Fagron NV FAGR.BR · Stock Open Fagron NV in new tab
Fagron NV Analysis (FAGR.BR)
Is Fagron NV a good investment? Fagron NV (FAGR.BR) is currently trading at 24.10 EUR. Market analysts have a consensus price target of 28.25 EUR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 19.35. This valuation is generally in line with the broader market.
Earnings Schedule: Fagron NV is expected to release its next earnings report on July 30, 2026. The market consensus estimate for Forward EPS is 1.65.
For income investors, Fagron NV pays a dividend yield of 1.17%. With a payout ratio of 29%, the dividend appears sustainable.
Investor FAQ
Does Fagron NV pay a dividend?
Yes, it pays an annual dividend of 0.28 EUR (1.17% yield).
What asset class is Fagron NV?
Fagron NV is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of 1.24.
Company Profile
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments. It also offers education and professional development of prescribers, hospitals, and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
| Year | Total Dividends |
|---|---|
| ▸2027 |
0.58 EUR
|
| May 18, 2027 (estimated) | 0.5811 |
| ▸2026 |
0.40 EUR
|
| May 20, 2026 | 0.4000 |
| ▸2025 |
0.35 EUR
|
| May 21, 2025 | 0.3500 |
| ▸2024 |
0.30 EUR
|
| May 23, 2024 | 0.3000 |
| ▸2023 |
0.25 EUR
|
| May 17, 2023 | 0.2500 |
| ▸2022 |
0.20 EUR
|
| May 18, 2022 | 0.2000 |
| ▸2021 |
0.18 EUR
|
| May 19, 2021 | 0.1800 |
| ▸2020 |
0.08 EUR
|
| May 18, 2020 | 0.0800 |
| ▸2019 |
0.12 EUR
|
| May 20, 2019 | 0.1200 |
| ▸2018 |
0.10 EUR
|
| May 22, 2018 | 0.1000 |
| ▸2015 |
0.93 EUR
|
| May 18, 2015 | 0.9259 |
| ▸2014 |
0.67 EUR
|
| May 19, 2014 | 0.6666 |
| ▸2013 |
0.56 EUR
|
| May 20, 2013 | 0.5555 |
| ▸2012 |
0.46 EUR
|
| May 21, 2012 | 0.4629 |
| ▸2011 |
0.41 EUR
|
| May 16, 2011 | 0.4074 |
| ▸2010 |
0.33 EUR
|
| May 17, 2010 | 0.3333 |
| ▸2009 |
0.28 EUR
|
| May 18, 2009 | 0.2778 |
| ▸2008 |
0.06 EUR
|
| May 15, 2008 | 0.0556 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Fagron NV | May 20, 2026 | Paid | 0.4 EUR |
| Split Date | Split Ratio to 1 |
|---|---|
| June 17, 2016 | 1.080000 |
Community Discussion